Use the PitchBook Platform to explore the full profile. View Judith Li’s profile on LinkedIn, a professional community of 1 Company . The syndicate also includes Lilly Asia Ventures, Foresite Capital and Eight Roads Ventures. Prior to his current role, Yi worked at Eli Lilly and Company in business development licensing and corporate ventures. Our Social Approach. Mar 22, 2024 · Lilly-backed Lilly Asia Ventures has also funded several Chinese biotechs, including Abbisko, Carsgen, Chipscreen Biosciences and others. Judith J. About 75% of companies that Lilly Asia Ventures invests in have a Jul 6, 2022 · Eli Lilly Lilly Asia Ventures Legend Capital. Opposing the other organizations, this Lilly Ventures Jul 29, 2021 · Kumquat brings together an accomplished team and distinguished scientific founder with a proven track record of innovative oncology drug discovery and development. The real fund results show that this VC is 8 percentage points more often commits exit comparing to other companies. The funding will be used to develop a portfolio of five therapeutic candidates to Lilly Asia Ventures is the sole investor for this series A round. We are invested in advancing science and supporting emerging medicines and technologies in early stages, within our core therapeutic areas and beyond. Sep 5, 2023 · Information on investments, active portfolio, exits, fund performance, dry powder, team and co-investors for Lilly Asia Ventures. lillyasiaventures. The fund targets investments in the pharmaceutical, biotechnology, life science, oncology and manufacturing sectors. The investment was led by Goldman Sachs, with Lilly Asia Ventures as co-investor. and LAV Fund VI Opportunities, L. Related AstraZeneca forecasts stronger China sales as CEO May 19, 2021 · Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm founded in 2008, with offices in Shanghai, Hong Kong, and Menlo Park. Jun 10, 2021 · The round was co-led by Deerfield Management and Janus Henderson Investors, with participation from RA Capital Management, Rock Springs Capital, Omega Funds, TCG X, Lilly Asia Ventures, and an undisclosed leading healthcare investor. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union Army veteran of the American Civil War for whom the company was later named. Sep 28, 2020 · InventisBio, a clinical stage biotech company dedicated to the research and development of innovative small molecule drugs, announced the recent completion of a $147 million series D financing which has attracted participation of many top biopharmaceutical and healthcare venture capital funds. May 28, 2024 · Lilly Asia Ventures has 7 Partners, 8 Venture Partners and 11 Principals Team location: Lilly Asia Ventures team is located in China , United States and 1 more June 22, 2021. Lilly Asia Ventures has 1 board member or advisor, Li Kaixin. Yi Shi is the Founder and Managing Partner of Lilly Asia Ventures, a leading biomedical venture capital firm with focus on China. Get Contact Info for All Departments. 礼来亚洲基金（LAV）是一家卓越的专注于生命科学和医疗健康行业投资的风险基金，总部位于中国上海，并在中国香港和美国硅谷设有办公室。. Company . Aug 12, 2020 · Description. 5 million Series A financing led by OrbiMed Advisors and joined by Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital and Lilly Asia Ventures. Experience: Lilly Asia Ventures 礼来亚洲基金 · Location: Boston · 500+ connections on LinkedIn. Contacts. Ltd. com), focused on developing innovative medicines for patients with central nervous system (CNS) diseases, today announced its launch and a $100 million Series Mar 26, 2024 · “With the support of our new and existing investors, including OrbiMed, Foresite Capital, SR One, Lilly Asia Ventures and Surveyor Capital (a Citadel company), we are in a strong position to advance our potentially best-in-class CDK2 inhibitor, AVZO-021, expand our pipeline with additional assets, and continue to grow our team. Proceeds will be used to advance the company’s discovery platform, which combines state-of-the-art computational chemistry, world-leading structural biology, and large-scale data integration to design orally available medicines with superior properties that overcome current limitations 直接联系Andiely. Dezhi holds a Ph. , 3SBio Inc. Lilly Catalyze360. S. We know that breakthrough medicines require tremendous amounts of resources and persistence, and we have industry-leading capabilities to cultivate your idea and help reach How PitchBook sources data. China China Eli Lilly-backed CRO ClinChoice says its new $150 million investment will fund growth through acquisitions and internal expansion. NEW YORK and HONG KONG, June 22, 2021 /PRNewswire/ -- Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million Series C financing led by Warburg Pincus. The company was launched in 2019 and has raised over $100 million from OrbiMed, Sequoia Capital China, EcoR1, Lilly Asia Ventures, and Roche Venture Fund. Their most recent diversity investment was on Mar 6, 2024, when Alumis raised. Sep 16, 2015 · Our data operations team has logged over 3. Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto. at their hard cap. Research…. We work with global health systems and organizations to extend our reach by being part of the solution for complex global health challenges that disproportionately affect people living in settings with limited Mar 6, 2024 · Editor's note: This article was updated at 5 p. Makes venture capital investments in Asia for Eli Lilly and Company, a global innovation-driven pharmaceutical. Lilly Asia Ventures Lilly Asia Ventures, founded in 2008 and headquartered in Shanghai, is a life sciences and healthcare sector focused venture capital firm, focusing predominantly on biopharmaceutical, med tech and diagnostics investments in Asia, particularly in China. The financing was also participated by May 30, 2013 · Lilly Asia Ventures I is a venture capital fund managed by Lilly Asia Ventures. Our approach to social impact starts with our medicines and our goal to expand access to quality health care. . Shanghai. Overview. The high activity for fund was in 2009. John Ma, Ph. Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. 35 billion for its latest healthcare fund, having introduced a $450 million opportunity vehicle that sits alongside a core pool of $900 million. Dr. Yi Shi is the Founder and serves as Managing Partner at Lilly Asia Ventures. Dec 8, 2020 · Lilly Asia Ventures Fund and Arch Venture Partners co-lead $100M Series A financing to advance the establishment of a robust and innovative CNS pipeline SHANGHAI – December 8, 2020 – SciNeuro Pharmaceuticals (www. 工作经历: Lilly Asia Ventures · 地点: 上海市 · 500 多位领英好友。 Proud and honored to be part of the passionate and dedicated Shoreline team Lilly Asia Ventures Venture capital Claimed. The Lilly Asia Ventures management team includes Judith Li (Partner), Wendy Luo (Chief Financial Officer, Usd Funds), and Yi Shi (Managing Director) . Nov 10, 2023 · Insight leads $50m round for Australia's Roller. This list of organizations invested in by Lilly Asia Ventures provides data on their funding history, investment activities, and acquisition trends. Phone Number (317) 429-0140. , is currently a Venture Partner of Lilly Asia Ventures and is widely recognized for his expertise in cancer and medicinal chemistry research. Jan 24, 2018 · Ping An Ventures, the direct investment arm of China’s Ping An Insurance, and Lilly Asia Ventures took part in the $100-million Series A financing round of Tmunity Therapeutics, the US-based immunotherapy developer that aims to fast-track the development of its T-cell-based personal cancer treatments. LAV Fund VI is a venture capital fund managed by Lilly Asia Ventures. The fund targets investments in the healthcare sector. LAV’s vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health. Proceeds of the Series D financing will be used to fund the His extensive knowledge and insights of the field neuroscience led to the founding of SciNeuro Pharmaceuticals in late 2020 to tackle the development of innovative therapeutics for CNS diseases. October 17, 2016. He serves as Board Member at Ansun Biopharma, BrightGene Bio-Medical Technology Company, SciNeuro Pharmaceuticals, and Elpiscience Biopharmaceuticals. 25, 2019 /PRNewswire/ -- Recently, Fountain Medical Development Limited ("Fountain Medical" or "Company") announced its $62 mm Series D round financing. Feb 4, 2019 · February 4, 2019. . Our vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health. exits. in Biochemistry and May 24, 2024 · Their most recent investment was on May 24, 2024, when Yanming Biology raised Lilly Asia Ventures has made 19 diversity investments. Lilly Asian Ventures invests in promising life science companies with strong management teams and innovative technology and/or business models. scineuro. · 工作经历: Lilly Asia Ventures · 教育经历: TongJi Medical College of HUST · 地点: 黄浦区 · 500 多位领英好友。. The Shanghai-based entity has over 80 companies in its investment portfolio, including Innovent Biologics Inc. these companies, their management team, and recent news are also included. www. in Molecular and Medical Pharmacology from UCLA and B. All investors from the Series Pre-A financing, K2VC, Gaorong Capital, and Chang'an Capital Sep 14, 2021 · About Lilly Asia Ventures (LAV) Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm established in 2008. The fund is located in Shanghai, China and invests in Asia. Current investors Lilly Asia Ventures, Oriza, Chang'an Capital, LYFE Capital, and K2VC also participated Liked by Stacie (Zongxi) Li. His education includes a Ph. 在领英 (一个拥有 10 亿会员的职业社区) 查看Andiely Lu的职业档案。. Investors > Lilly Asia Ventures. com. 14, 2019 (GLOBE NEWSWIRE) -- Passage Bio today debuted with a $115. Yi Shi serves as Director at Betta Pharmaceuticals. Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Feb 27, 2019 · Kirkland & Ellis has advised Lilly Asia Ventures (LAV), a leading biomedical venture capital firm, in a one and final closing of its fifth USD life sciences fund, LAV Biosciences Fund V. Information on investments, limited partners, investment strategy, team and returns for Lilly Asia Ventures RMB Fund II. Prior to the current assignment, he worked in various roles with increasing responsibility over six years at Eli Lilly and Company. The usual things for fund are deals in the range of 10 - 50 millions dollars. Existing investors The Column Group, Samsara BioCapital, Canaan Partners, and Emerson Collective also Oct 20, 2021 · With the completion of the Series B financing, ShouTi has raised $158 million since initiating operations. Experience: Lilly Asia Ventures · Education: Harvard Business School · Location: Menlo Park · 500+ connections on LinkedIn. Aug 3, 2021 · Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. m. Lilly Asia Ventures's most notable exits include ProfoundBio , Gritstone bio , and Alector. The biotech has three clinical-stage Nov 2, 2015 · Lilly Asia Ventures, founded in 2008, is dedicated to venture capital investments in the life sciences and healthcare sectors in Asia, particularly in China. The fund investment amount ranges from USD 5 million to USD Description. Yaolin Wang, InventisBio Chairman and CEO. , which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery, today announced the successful completion of approximately $10 Million in a Series pre-B Plus financing, and strengthening of Dec 14, 2022 · Dr. Jun 24, 2015 · Experience: Lilly Asia Ventures 礼来亚洲基金 · Education: University of California, Los Angeles · Location: San Francisco Bay Area · 500+ connections on LinkedIn. 35b for healthcare funds. “We are strong believers in the promise of small molecule therapeutics that target immune cells in the tumor microenvironment,” said Brad Bolzon, managing director and chair of Versant and Tempest. Find Tao's email address, mobile number, work history, and more. -based Eli Lilly and Company in business development licensing and corporate ventures. Lilly Asian Ventures makes venture capital investments in Asia for Eli Lilly and Company, a global innovation-driven pharmaceutical company. Founder, Chairman and CEO at RONOVO Surgical. BEIJING and SHANGHAI , Oct. Australasia. Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe. ET to clarify Lilly Asia Ventures' association with Eli Lilly, and to differentiate between Foresite Labs and Foresite Capital. Its products are sold in approximately 125 countries. 5 million hours researching, organizing, and integrating the information you need most. Boston, MA, October 17, 2016 - Veritas Genetics, a global leader in accessible genetic testing, announced $30 million in Series B funding from existing backer Lilly Asia Ventures and new investors Trustbridge Partners and Jiangsu Simcere Pharmaceutical. 10 November 2023. and SUZHOU, China, July 12, 2021 /PRNewswire/ -- ProfoundBio announced the closing of a $55+ million Series A financing round co-led by Lilly Asia Ventures (LAV) and LYFE Capital, with participation from Sequoia Capital China and Oriza. "The new investment will accelerate the development of our clinical candidates into phase 2 trials and help us developfirst-in-class drug candidates into clinical stage," said Dr. -- ( )--EdiGene Inc. Lilly Asia Ventures Fund III is venture capital fund managed by Lilly Asia Ventures. Asia Connect Oct 25, 2019 · October 25, 2019. A final close happened on January 22, according to a source close to the situation. Our data operations team has logged over 3. YANTAI, China, April 2, 2020 /PRNewswire/ -- RemeGen recently announced the closing of approximately USD $100 million in a private financing co-led by Lilly Asia Ventures and Lake Bleu Capital. The fund targets investments in the pharmaceutical, biotechnology, life science and oncology sectors. Room 2909-14, 168 Hubin Road, Huangpu District, Shanghai, China. SHANGHAI-- ( BUSINESS WIRE )--SciNeuro Pharmaceuticals ( www. Prior to joining LAV, Dezhi was an Associate Director at Navigant Consulting, providing commercial strategy support to pharma and biotech companies. “We believe that MabSpace has built a differentiated approach rooted in its unique immune tolerance breaking based antibody discovery platform and translational science capabilities that position it to bring the next wave of innovation to the field,” said Stephen Lin Experience: Lilly Asia Ventures 礼来亚洲基金 · Education: Harvard Business School · Location: Greater Boston · 500+ connections on LinkedIn. Judith holds board appointments at a variety of LAV’s portfolio companies, including Crown Biosciences Jun 2, 2022 · WOODINVILLE, Wash. His experience includes leading the development of a comprehensive investment strategy for China as well as negotiating. Sep 10, 2021 · OrbiMed Advisors and Lilly Asia Ventures are two key players pouring money into RNA-targeting technology via ADARx Pharmaceuticals’ $75 million series B round. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, LAV Feb 13, 2024 · The likes of Lilly Asia Ventures, RA Capital Management, OrbiMed, Medicxi and LifeSci Venture Partners all featured in the $112 million round, which was led by Ally Bridge Group. The vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health. Prior to founding LAV in 2008, Yi worked at the U. This round of investment is supported by well-known global institutional investors such as Vivo Capital, Janchor Partners, OrbiMed Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm founded in 2008, with offices in Shanghai, Hong Kong, and Palo Alto. BEIJING & CAMBRIDGE, Mass. Jan 22, 2021 · Description. Apr 4, 2018 · The hot nonalcoholic steatohepatitis (NASH) arena has a new player, Terns Pharmaceuticals, and it has already got three programs from Eli Lilly and a $30 million series A backed by Lilly Asia Ventu Aug 15, 2017 · Lilly Asia Ventures, the Asia-focused biomedical venture capital firm sponsored by US-based pharmaceutical firm Eli Lilly, has closed its fourth fund at $450m, AltAssets reported yesterday. Yi is the founder and managing partner of Lilly Asia Ventures (LAV). Licensed Surgeon -> Management Consultant -> Biotech & Healthcare…. The fund was heavily oversubscribed with a broad mix of global institutional investors, including sovereigns, pensions, endowments, foundations, family offices April 2, 2020. · Experience: Lilly Asia Ventures 礼来亚洲基金 · Education: University of California, Los Angeles · Location: Menlo Park · 500+ connections on Mar 11, 2019 · Also participating were existing investors Lilly Asia Venture (LAV) and OrbiMed Asia. Lilly Asia Ventures has had. D. Previously, Dr. 提供行业经验、全球资源和长期资本. , and Betta Pharmaceuticals Co. biopharmaceuticals, human therapeutics, medical devices, and diagnostics. The fund is located in Shanghai, China and invests in Mainland China. com ), focused on developing innovative medicines for patients with central nervous system (CNS) diseases, today announced its launch and a $100 million Series A financing, co-led by Lilly Asia Ventures and Arch Venture Partners. View Dezhi Kang’s Dezhi Kang is a Vice President with Lilly Asia Ventures (LAV). Contact Email lilly_ventures@lilly. Li is a Partner at Lilly Asia Ventures (LAV), based in Hong Kong / Shanghai and focused on early and growth stage investments across biopharmaceuticals, medical devices, and diagnostics both domestically and cross-border. The fund is located in Shanghai, China. Jul 7, 2015 · Information on investments, limited partners, investment strategy, team and returns for Lilly Asia Ventures RMB Fund I. Feb 8, 2021 · Kirkland Represents Lilly Asia Ventures in Successful Closing of Sixth Life Sciences Funds 08 February 2021 Kirkland advised Lilly Asia Ventures (LAV), a leading biomedical venture capital firm, in the one and final closing of its sixth USD life sciences funds, LAV Fund VI, L. The round, led by Trustbridge Partners, a global growth equity investor Jun 19, 2019 · Lilly Asia Ventures is a biotechnology-focused venture capital company with around $2 billion in committed capital. Lilly Asia Ventures 礼来亚洲基金 | 1,387 followers on LinkedIn. Min also currently serves as a venture partner at Lilly Asia Ventures (LAV) and director of Adagene (ADAG, NASDAQ). Information on investments, active portfolio, exits, fund performance, dry powder, team and co-investors for Lilly Ventures. in Biotechnology from Peking University. LAV Biosciences Fund IV was heavily oversubscribed and took only two months to reach its hard cap, according to Alt Assets, though a regulatory filing December 8, 2020. View Pengpeng Li’s profile on LinkedIn, a professional community of 1 billion members. Joe (Chuan) Shih, Ph. P. Jul 12, 2021 · WOODINVILLE, Wash. and SUZHOU, China, June 2, 2022 /PRNewswire/ -- ProfoundBio, a biotech company focusing on the development of novel targeted therapies, announced the closing of a $70 million Series A+ financing round led by Sequoia China. The increased amount of exits for fund were in 2018. The fund prefers minority stake. LAV's vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that can treat diseases and improve human health. View Susie Wang, PhD, MBA’s profile on May 9, 2023 · INDIANAPOLIS, May 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has allocated an additional $50 million to its now $300 million Social Impact Venture Capital Portfolio, reflecting the company's commitment to going beyond the medicines it makes to have a positive impact on patients and society through for-profit investments. Judith Li, a partner with Lilly Asia Ventures, discusses healthcare investment opportunities in China, Greater China, Healthcare, Early-stage, China, Venture, Lilly Asia Ventures, Avcjtv. Dec 8, 2020 · Lilly Asia Ventures Fund and Arch Venture Partners co-lead $100M Series A financing to advance the establishment of a robust and innovative CNS pipeline The SciNeuro leadership team includes View Tao Yu's business profile as Healthcare Investment Professional at Lilly Asia Ventures 礼来亚洲基金. Yi Shi joined Lilly Asian Ventures in 2007 as a Managing Director based in Shanghai, China. Lilly Asia Ventures RMB Fund IV is a 2019 vintage venture capital fund managed by Lilly Asia Ventures. Insights about top trending companies, startups, investments and M&A activities, notable investors of. Dec 14, 2021 · Information on investments, limited partners, investment strategy, team and returns for Lilly Asia Ventures RMB Fund V. Feb 15, 2024 · ProfoundBio picked up $112 million from Ally Bridge Group, Lilly Asia Ventures, RA Capital Management, OrbiMed, Medicxi and LifeSci Venture Partners. The fund targets investments in the healthcare and life science sectors. ” Lilly Asia Ventures has 3 current employee profiles, including Managing Director & Founder Yi Shi. Its primary goal is to facilitate the success of companies in its areas of focus through early to expansion stage investments and value-adding Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm founded in 2008, with offices in Shanghai, Hong Kong, and Palo Alto. He also served as Board Member at CPC Scientific and PHILADELPHIA, Feb. Shih was the Distinguished Investigator and Director of Institute of Biotechnology and Pharmaceutical Research (IBPR) of National Health Research Institutes (NHRI), a… Nov 10, 2023 · Lilly Asia Ventures raises $1. Lilly Asia Ventures (LAV) has raised $1. woykmblpvtkttlwovufg